Membrane transporters can be major determinants of the pharmacokinetic, safety and
efficacy profiles of drugs. This presents several key questions for drug development …

Uptake and efflux transporters determine plasma and tissue concentrations of a broad
variety of drugs. They are localized in organs such as small intestine, liver, and kidney …

The importance of membrane transporters for drug pharmacokinetics has been increasingly
recognized during the last decade. Organic anion transporting polypeptide 1B1 (OATP1B1) …

Transporters in proximal renal tubules contribute to the disposition of numerous drugs.
Furthermore, the molecular mechanisms of tubular secretion have been progressively …

Drug discovery and development involve the utilization of in vitro and in vivo experimental
models. Different models, ranging from test tube experiments to cell cultures, animals …

Lipid‐lowering drugs, especially 3‐hydroxy‐3‐methylglutaryl–coenzyme A inhibitors
(statins), are widely used in the treatment and prevention of atherosclerotic disease. The …

The hepatic organic anion transporting polypeptides (OATPs) influence the
pharmacokinetics of several drug classes and are involved in many clinical drug–drug …

3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely
used for the treatment of hypercholesterolemia. Their efficacy in preventing cardiovascular …

Statins are a class of drugs used to lower low-density lipoprotein cholesterol and are
amongst the most prescribed medications worldwide. Most statins work as a competitive …

The ATP-binding cassette transporter G2 (ABCG2; also known as breast cancer resistance
protein, BCRP) has been suggested to be involved in clinical multidrug resistance (MDR) in …